Dorf Ketal and Lehmann&Voss&Co. expand sales partnership

Published: 7-Feb-2023
Distribution Manufacturing Regulatory

The LEHVOSS Group under the management of Lehmann&Voss&Co. is a group of companies in the chemicals sector

Dorf Ketal Chemicals and Lehmann&Voss&Co. are expanding their long-standing cooperation in the sale of TYZOR brand organotitanates and organozirconates as well as UNILINK and CLEARLINK brand diamines. 

In this context, Lehmann&Voss&Co. will take over the distribution rights for Switzerland and Austria in addition to the existing distribution rights for Germany with effect starting on February 1, 2023.

TYZOR brand organotitanates and organozirconates as well as UNILINK and CLEARLINK brand diamines are used in particular as adhesion promoters, catalysts and chain extenders for paint, printing ink, construction chemical, adhesive and sealant applications as well as for rigid foams, elastomers and chemical synthesis and production.

The LEHVOSS Group under the management of Lehmann&Voss&Co. is a group of companies in the chemicals sector that develops, produces and markets chemical and mineral specialities for various industrial clients.

  • Companies:
  • Lehvoss
See more

You may also like

Manufacturing

LEHVOSS expands compounding facility in China

Read more
The company has relocated to a different site which means it can expand its high-performance compounding and pharmaceutical technology capabilities

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

LEHVOSS expands compounding facility in China

The company has relocated to a different site which means it can expand its high-performance compounding and pharmaceutical technology capabilities
Manufacturing

WuXi AppTec peptide facility receives PMDA approval

The company's Changzhou oligonucleotide API manufacturing site was approved by Japan's Pharmaceuticals and Medical Devices Agency
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Ardena's nanomedicines facility marks expansion with first GMP approval

The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Manufacturing

Transforming healthcare with patient centricity

In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact they’re having on the pharmaceutical industry
Subscribe now